Mandate

Vinge advises G-Loot in its half a billion SEK financing round

Vinge has advised the esports company G-Loot Global Esports AB (publ) in connection with its financing round of SEK 500 million - one of the largest esports fundraises globally.

The investment round was completed through a private placement of shares to new investors and certain larger current owners. G-Loot will now focus on expanding its service across gaming platforms, growing the player base and creating a strong, global brand.

G-Loot is the world’s first online esports platform for mobile and PC games where players can compete against each other and win real cash prices. G-Loot democratizes competitive esports by its mission to make it possible for anyone, anywhere in the world, to earn money by playing their favourite games online.

Vinge’s team primarily consisted of Jonas Johansson, Filip Öhrner, Christina Odengran, David Andersson, Rikard Lindahl and Joel Magnusson.

 

Related

Vinge has advised Morrow Bank AB (publ) in conjunction with the acquisition of MedMera Bank AB

Vinge has advised Morrow Bank AB (publ) in conjunction with the acquisition of all shares in MedMera Bank AB from Kooperativa Förbundet for a total consideration of SEK 1,960 million. The transaction positions Morrow Bank as a leading Nordic platform in consumer finance with combined gross loans of SEK 28.2 billion.
March 24, 2026

Vinge advises NEWS, a portfolio company of Litorina, in connection with the sale of Skandinavisk Kommunalteknik, FANN VA-Teknik and Alunda Polyeten to Wienerberger AG

Vinge advises Northern Environmental and Water Solutions AB (“NEWS”), a portfolio company of Litorina, in connection with the sale of the operating subsidiaries Skandinavisk Kommunalteknik, FANN VA-Teknik and Alunda Polyeten to Wienerberger AG (Vienna Stock Exchange: WIE). The transaction is expected to be completed in Q2 2026.
March 24, 2026

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026